Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

December 05, 2019 08:15 ET | Source: Zogenix, Inc.

Zogenix to Host Investor Update Lunch on FINTEPLA® at the American Epilepsy Society 2019 Annual Meeting

EMERYVILLE, Calif., Dec. 05, 2019 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ: ZGNX), a global pharmaceutical company developing rare disease therapies, today announced that it will host an Investor...
November 07, 2019 16:01 ET | Source: Zogenix, Inc.

Zogenix Provides Corporate Update and Reports Third Quarter 2019 Financial Results

Resubmitted NDA for FINTEPLA® for the treatment of Dravet syndromeEnrollment completed for FINTEPLA global Phase 3 trial in Lennox Gastaut syndrome; top-line data anticipated in Q1 2020Acquired Modis...
October 31, 2019 08:00 ET | Source: Zogenix, Inc.

Zogenix to Release Third Quarter 2019 Financial Results and Host Conference Call and Webcast on November 7

EMERYVILLE, Calif., Oct. 31, 2019 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ: ZGNX), a global pharmaceutical company developing rare disease therapies, today announced that it will report its...
October 25, 2019 09:00 ET | Source: Zogenix, Inc.

Zogenix Announces New Positive Data for Its Investigational Drug FINTEPLA® in Dravet Syndrome

Data have shown long-term, clinically meaningful convulsive seizure reduction (75.5%; p<0.001) in Dravet syndrome patients under 6 years old, as well as clinically meaningful and profound reduction...
September 09, 2019 08:00 ET | Source: Zogenix, Inc.

Zogenix Completes Acquisition of Modis Therapeutics, Inc.

EMERYVILLE, Calif., Sept. 09, 2019 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ: ZGNX), a global pharmaceutical company developing rare disease therapies, today announced that it has successfully...
August 26, 2019 07:00 ET | Source: Zogenix, Inc.

Zogenix Announces Acquisition of Modis Therapeutics, Inc.

Advances Zogenix’s strategy to provide transformative therapies to patients and families living with serious rare diseasesAdds MT1621, a proprietary, late-stage investigational medicine targeting...
July 08, 2019 08:00 ET | Source: Zogenix, Inc.

Zogenix Completes Enrollment in Phase 3 Trial of FINTEPLA® in Lennox-Gastaut Syndrome

EMERYVILLE, Calif., July 08, 2019 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ: ZGNX), a global pharmaceutical company developing rare disease therapies, today announced that it has completed...
June 27, 2019 08:00 ET | Source: Zogenix, Inc.

Zogenix Announces FDA Agreement to Proceed with Resubmission of FINTEPLA® NDA

EMERYVILLE, Calif., June 27, 2019 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ: ZGNX), a global pharmaceutical company developing rare disease therapies, today announced that following receipt of final...
May 08, 2019 16:01 ET | Source: Zogenix, Inc.

Zogenix Provides Corporate Update and Reports First Quarter 2019 Financial Results

Type A meeting with U.S. FDA expected by early June to discuss FINTEPLA® Dravet syndrome NDA expected by early JuneFINTEPLA Dravet syndrome MAA accepted for review by EMAExclusive distribution...
May 07, 2019 08:00 ET | Source: Zogenix, Inc.

Zogenix to Participate in the Bank of America Merrill Lynch 2019 Healthcare Conference

EMERYVILLE, Calif., May 07, 2019 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ: ZGNX), a global pharmaceutical company developing rare disease therapies, today announced that Stephen J. Farr, Ph.D.,...

Next Page keyboard_arrow_right